Blood Biomarkers for Neurodegeneration

Clinical MedicineUpdated Oct 5, 2026Version v1

Evidence

Public papers linked to this topic and used as evidence for gaps, timelines, and knowledge views.

198 papers

Showing 13-24 of total 198 evidence records.

Open a paper to inspect abstract, source links, and topic context.

2026PubMedSupporting evidence

Excitation-inhibition imbalance links amyloid pathophysiology to cognition in non-demented individuals.

Zhang S; Roemer-Cassiano SN; Chong JR; Fang T; Li Y; Wang Z; Zeng T; Li X; Deco G; Venketasubramanian N; Zhou JH; Chen CL; Alzheimer's Disease Neuroimaging Initiative; Lai MKP; Franzmeier N; Yeo BTT

2026PubMedDirectly related

A single-center open-label, randomized, parallel-group controlled clinical trial on the long-term effect of the treatment with EGb 761 in blood markers of inflammation and neurodegeneration in patients with mild cognitive impairment: ACE-2020-EGb 761.

Morato X; Marquié M; Tartari JP; Lafuente A; Sáez ME; Montoliu-Gaya L; Huber H; Alegret M; Jofresa S; Buendía M; Pancho A; Aguilera N; Ibarria M; Diego S; Cuevas R; Cañada L; Pérez-Cordón A; Sanabria A; De Rojas I; Cano A; Orellana A; Montrreal L; Rosende-Roca M; Vargas L; Espinosa A; Ortega G; Núñez-Llaves R; Martínez-Lucas M; Cantero-Fortiz Y; Alarcón-Martín E; Gurruchaga M; Tárraga L; Valero S; Sanz-Cartagena P; Mañes S; Zetterberg H; Ruiz A; Boada M

Jan 1, 2026Journal of Alzheimer's disease : JAD

2026PubMedDirectly related

Preliminary insights into whole-blood mitochondrial DNA copy number and telomere length in Parkinson's disease and multiple system atrophy.

Gagliardi M; Felicetti A; Procopio R; Augimeri A; Morelli M; Quattrone A; Annesi G; Quattrone A

Jan 1, 2026Journal of neurology

2026PubMedDirectly related

Understanding Alzheimer's disease through biomarkers: pathology, progression, and clinical application.

Zhang XT; Murphy M; Riordan H; Wang K; Esquivel R; Xu W; Zhang X; Gong X; Sun Y; Lu Y

Jan 1, 2026Bioanalysis

2026PubMedSupporting evidence

Highly sensitive and specific high-throughput detection of Aβ42 in clinical specimens using a G-quadruplex-structured fluorescent aptamer analysis platform.

Cui M; Yang J; Zhao LS; Hu X; Cong W; Hu H; Xu F; Liu S

Jan 1, 2026Talanta

2026PubMedSupporting evidence

The Impact of Age, Comorbidity, and Current Medication Use on Plasma p-tau217 in Adolescents: A Pilot Study.

Stancil SL; Brewe ME; Mayfield H; Morris J

Jan 1, 2026The journal of applied laboratory medicine

2026PubMedDirectly related

14-3-3γ Protects Against Postoperative Cognitive Dysfunction by Regulating Tau Thr205 Phosphorylation and Synaptic Integrity.

Zhu S; Han X; Zhang H; Ye C; Xia T; Gu X

Jan 1, 2026Advanced science (Weinheim, Baden-Wurttemberg, Germany)

2026PubMedDirectly related

Unbiased bioinformatic and clinical analysis identifies glial fibrillary acidic protein as a potential biomarker in spinal muscular atrophy.

Soares de Oliveira KL; Weber AC; Becker MM; Magalhães JSA; de Albuquerque ALA; Chadanowicz JK; Giudicelli GC; Rohden F; Zimmer ER; Kowalski TW; Siebert M; Costa MCM; Saute JA

Jan 1, 2026Brain communications

2026PubMedDirectly related

Epitope placement tunes CSF tau biomarkers: Comparison of P-tau217 and BD-tau designs.

Gleerup HS; Musaeus CS; Santos C; Kvartsberg H; Harrison P; Turton M; Zetterberg H; Frederiksen KS; Hasselbalch SG; Simonsen AH; Ortiz FG

Jan 1, 2026Molecular neurodegeneration advances

2026PubMedSupporting evidence

Erinacine C Attenuates Alzheimer's-like Pathology: A Study in APP/PS1 Mice and PC12 Cells.

Wang LY; Yeh SL; Hsu ST; Huang SM; Chau CF; Chuang CH

Jan 1, 2026Molecules (Basel, Switzerland)

2026PubMedSupporting evidence

Bioengineered microbiotic levodopa therapy improves cognition and reduces pathology in a rat model of Alzheimer's disease.

Abdelhamid M; Padhi P; Gifani M; Beck JS; Thomas JP; Khadse G; Kudela C; Phillips GJ; Kanthasamy AG; Counts SE

Jan 1, 2026British journal of pharmacology

2026PubMedSupporting evidence

Trans-Vitisin B Targets Neuroinflammation, Oxidative Stress, and Tau Pathology to Improve Behavioral Outcomes in a Mouse Model of Parkinson's Disease.

Pislyagin E; Manzhulo I; Agafonova I; Starinets A; Menchinskaya E; Chingizova E; Tarbeeva D; Fedoreyev S; Aminin D

Jan 1, 2026Antioxidants (Basel, Switzerland)